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ABSTRACT
Objective: To evaluate the vascular response at
9 months after zotarolimus-eluting stent (ZES; Endeavor)
implantation using optical coherence tomography (OCT).
These findings were compared with those after implan-
tation of a sirolimus-eluting stent (SES; Cypher Select).
Design: Cross-sectional observational study with pro-
spective OCT registry.
Setting: Nine months after ZES or SES implantation.
Patients and methods: A total of 68 patients (32 ZES
and 36 SES) underwent OCT at 9 months after stent
implantation. The neointima hyperplasia (NIH) thickness
inside each strut and percentage of NIH area at every
1 mm cross section were measured.
Main outcome measurement: The degree of neointimal
coverage and the prevalence of malapposition at
9 months after ZES and SES implantation using OCT.
Results: The mean (SD) NIH thickness (251.2
(110.0) mm vs 85.5 (53.3) mm, p,0.001) and percen-
tage of NIH area (27.9 (9.1)% vs 11.2 (7.1)%, p,0.001)
were significantly greater in ZES than in SES. The
prevalence of uncovered strut as well as malapposed
strut was significantly lower in ZES than in SES (0.3% vs
12.3%, p,0.001 and 0.08% vs 2.6%, p,0.001).
Thrombus was not observed in ZES (0.0% in ZES vs
27.8% in SES, p = 0.001).
Conclusions: Neointimal coverage in ZES was almost
complete and malapposition was very rare at 9-months’
follow-up.
Although in-stent restenosis (ISR) was remarkably
reduced after introduction of the drug-eluting stent
(DES), excessive inhibition of neointima formation
caused delayed arterial healing with incomplete
endothelialisation over the stent strut.1 2 A recent
autopsy study showed that the most important
histological and morphometric predictors of late
stent thrombosis (LST) were endothelial coverage
and the ratio of uncovered to total stent struts
after DES implantation.3 Therefore, identification
of neointima over stent struts could provide
important information to predict LST. In compar-
ison with the first generation DES, a zotarolimus-
eluting stent (ZES) has different inhibition proper-
ties for neointimal hyperplasia (NIH).4 The ZES
has been shown to have a significantly higher rate
of neointimal coverage than the sirolimus-eluting
stent (SES) on intravascular ultrasound (IVUS) at
8 months after implantation.5 However, the reso-
lution of conventional IVUS (100–150 mm) was
inadequate to identify neointima over stent struts
because a considerable portion of neointima are
,100 mm thick.5
Intravascular optical coherence tomography
(OCT) can identify thin layers of neointima and
malapposition with its high resolution (10–
20 mm).6 7 Several studies have reported that OCT
evaluation of stent strut coverage of bare metal
stents (BMS) and SES.6 7 However, OCT data
regarding the degree of neointimal coverage and
malapposition after ZES stenting are limited.
Therefore, this study was undertaken to evaluate
neointimal coverage and malapposition at
9 months after ZES implantation using OCT.
MATERIAL AND METHODS
Study population
One hundred and seventy-nine patients treated
with ZES (Endeavor; Medtronic, Santa Rosa,
California, USA) or SES (Cypher Select; Cordis,
Miami Lakes, Florida, USA) (90 SES and 89 ZES)
who fulfilled inclusion and exclusion criteria were
consecutively enrolled in this study between
November 2006 and October 2007. The inclusion
criteria for this study were: (a) de novo lesion with
.50% diameter stenosis, which was related to
myocardial ischaemia; (b) native vessel size of 2.5–
3.5 mm in diameter; (c) stable angina or acute
coronary syndrome (ACS) including ST elevation
myocardial infarction; (d) non-overlapping stents.
The exclusion criteria included: (a) significant left
main coronary artery disease; (b) congestive heart
failure or low ejection fraction ((35%); (c) renal
insufficiency with baseline creatinine >2.0 mg/dl;
(d) lesions unsuitable for OCT with occlusive
technique (proximal vessel size .3.5 mm or
proximal lesions 15 mm from the ostium of each
artery). The choice of DES (ZES or SES) was made
according to the operator’s preference. The OCT
was performed in 68 patients (32 ZES and 36 SES)
during follow-up angiography at 9¡2 months.
Among 179 patients, we performed a follow-up
angiography in 120 patients between 7 and 11
months. Among 120 patients, OCT was performed
in only 80 patients because of difficulties and
refusal to undergo the OCT procedure.
Additionally, 12 stents were not completely
evaluated for the whole stent length, and, there-
fore, we excluded 12 stents after OCT evaluation.
The study protocol was approved by the
Institutional Review Board of Yonsei University
College of Medicine and written consent was
obtained from all patients.
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Angiographic analysis
Quantitative coronary angiography (QCA) was performed
offline using a quantitative coronary angiography analysis
system (CASS; Pie Medical Instruments, Maastricht, The
Netherlands) by a single person blinded to patients’ informa-
tion. Minimal luminal diameter (MLD) of treated coronary
segments, reference vessel diameter (RVD), percentage diameter
stenosis and lesion length on the baseline angiogram were
determined in the view that demonstrated lesions to be most
severe and not foreshortened. Post-procedure and follow-up
angiograms were evaluated in the same view.
OCT data collection and analysis
An OCT system (Model M2 Cardiology Imaging System;
LightLab Imaging, Westford, Massachusetts, USA) and a
0.014 inch wire-type imaging catheter (ImageWire; LightLab
Imaging) were used in this study. A 6 or 7 Fr guiding catheter
was introduced into the coronary artery by femoral or radial
approach. When the image wire had been positioned through
the occlusion balloon distal to the stent, the occlusion balloon
(Helios; Avantec Vascular, Sunnyvale, California) was inflated
to 0.4–0.6 atm and Ringer’s lactate was infused at 0.5–1.0 ml/s.
The image wire was pulled distal to proximal at a speed of
1 mm/s, and continuous images were stored digitally for
subsequent analysis. Cross-sectional OCT images were analysed
at 1 mm intervals (every 15 frames).
Among 1535 image sections, 1473 image sections (96.0%)
were analysable in this study (696/710 (98.0%) in ZES and 777/
825 (94.2%) in SES). Parameters were calculated and defined as
follows: distances between the endoluminal surface of neo-
intima and stent strut were measured with a measurement line
as perpendicular as possible to the neointima and strut.8 When
there was no definite neointima over the stent strut, we defined
it as an uncovered stent strut. Distances between the inner
surface of the strut reflection and the vessel wall were measured
by extending contours of the walls on the outside of the strut
shadow with a measurement line.8 The position of the stent
strut on the vessel wall was measured by magnifying the
individual stent strut to maximise accuracy when the strut was
not fully attached to the vessel wall as determined by visual
estimation. Stent malapposition was defined as struts with
detachment from the vessel wall >160 mm for SES and
>110 mm for ZES.9 Stent struts at bifurcation with major side
branches .2.0 mm in diameter were excluded from this
analysis. Thrombus was defined as an irregular mass protruding
into the lumen or intraluminal mass unconnected from the
surface of vessel wall that had a signal-free shadowing in the
OCT image.10 Percentage NIH was calculated as percentage NIH
area = ((stent area 2 lumen area)/stent area) 6100.
A cross section with uncovered strut was defined if one or
more stent struts was uncovered on cross section and a cross
section with uncovered strut ratio .0.3 was defined when the
ratio of uncovered struts to total stent struts per cross section
was more than 0.3.3 We identified the variation of NIH
thickness and the thickness of NIH at the thinnest and thickest
parts on each stent. We also evaluated the pattern for NIH
using a heterogeneity score as follows: the status of NIH
thickness at each cross section was divided into four grades;
grade 0, uncovered strut to total stent struts; grade 1, NIH
thickness ,100 mm, which was not detected with IVUS; grade
2, NIH thickness between 100 and 200 mm; grade 3, NIH
thickness.200 mm.11 The grade was determined as minimal and
maximal grade including >10% of stent struts at each cross
section. The heterogeneity score of NIH thickness in OCT was
determined by subtracting the minimal grade from the maximal
grade.
Clinical follow-up
All patients received dual antiplatelet therapy (DAT; aspirin and
clopidogrel) for at least 9 months. Death, non-fatal myocardial
infarction and LST were evaluated for 9 months.
Statistical analysis
Inter- and intraobserver variability in measurements of distance
and area were assessed by evaluation of 20 random cross-
sectional images by two independent readers and by the same
reader at two separate time points, respectively. Variations in
measurements were calculated using linear mixed models (one-
and two-way). Results are expressed as mean (SD) or number
(%). Comparisons of categorical variables were made using a x2
test and Fisher exact test while the Student t test was used to
compare continuous variables. If the distributions were skewed,
a non-parametric test was used. Because of the hierarchical
structure of data for all struts across stents and patients,
multilevel logistic analysis was applied for uncovered and
malapposed struts as the outcome variable to control for the
random and fixed effects of the strut, lesion and patient
characteristics. At the lesion level, lesion type (A, B1 or B2, C),
stent type (ZES vs SES), stent length, stent diameter, RVD,
MLD and maximum inflation pressure were considered. At the
patient level, age, sex, ACS and diabetes mellitus were
considered.
All analyses were performed using Statistical Analysis
Software (SAS) 9.1.3. (SAS Institute, Cary, North Carolina,
USA). A p value ,0.05 was considered statistically significant.
RESULTS
Baseline characteristics
Table 1 presents the baseline characteristics of patients.
Although DES were not randomly selected, baseline character-
istics were similar between the two stents groups. The mean
(SD) interval between stent implantation and OCT was also
similar between the two groups (289 (59) days in ZES vs 288
(69) days in SES, p = 0.95). The prevalence of ACS was 55.9% in
all patients and the left anterior descending artery was the most
commonly treated lesion in both groups (15 (46.9%) in ZES vs
18 (50.0%) in SES, p = 0.41).
The mean (SD) stent diameter was larger in ZES than SES
(3.1 (0.3) mm vs 2.9 (0.3) mm, p = 0.004), but stent length and
lesion type were similar in both groups (table 1). Maximal
balloon inflation pressure was 17.1 atm in ZES and 17.2 atm in
SES without significant difference in both groups (table 1).
Angiographic data
Preintervention QCA data were similar between the two groups
(mean (SD) RVD: 2.9 (0.3) mm in ZES vs 2.8 (0.4) mm in SES,
p = 0.25 and MLD: 0.8 (0.5) mm in ZES vs 0.7 (0.4) mm in SES,
p = 0.50). Although acute gain was similar between the groups,
both diameter stenosis and late loss at 9 months after
implantation were significantly greater in ZES (table 1).
OCT data
Table 2 shows the OCT data. Total measured stent length was
1535 mm including 16 563 struts (8497 in ZES and 8066 in SES).
Figure 1 shows representative OCT cases in ZES and SES.
Analysable stent struts for each cross section was greater in
ZES than SES (12.2 struts (8497/696) in ZES and 10.4 struts
Interventional cardiology
1908 Heart 2009;95:1907–1912. doi:10.1136/hrt.2009.167759
(8066/777) in SES). The mean (SD) stent area was significantly
larger in ZES than in SES (7.8 (1.7) mm2 vs 6.6 (1.6) mm2,
respectively, p,0.001), which was consistent with QCA.
Additionally, NIH area (2.2 (0.8) mm2 vs 0.7 (0.4) mm2,
p,0.001) and percentage of NIH area (27.9 (9.1)% vs 11.2
(7.1)%, p,0.001) were greater in ZES than in SES. The
intraobserver correlation coefficient of neointimal thickness or
distance and area between variability of a single observer was
0.981 (95% CI 0.975 to 0.985) and 0.997 (95% CI 0.993 to 0.999)
using a one-way mixed model, in which patient effects are
random. The interobserver correlation coefficient of neointimal
thickness or distance and area between the variability of two
observers using a two-way mixed model, in which patient
effects were random and observers’ effects were fixed, was 0.982
(95% CI 0.977 to 0.986) and 0.993 (95% CI 0.982 to 0.997).
In a comparison of neointima over the stent struts of ZES and
SES, it was found that most stent struts of ZES were covered
with neointima. However,.10% of stent struts in SES were not
covered with neointima (uncovered stent struts of ZES vs SES:
28/8497 (0.3%) vs 991/8066 (12.3%), p,0.001, fig 2). The rate of
malapposition (7/8497 (0.08%) vs 208/8066 (2.6%), p,0.01) and
uncovered stent strut with malapposition (1/8497 (0.001%) vs
199/8066 (2.5%), p,0.001) were significantly higher in SES
(fig 2). Cross sections with uncovered struts were detected more
frequently in SES than ZES. In particular, there were no cross
sections with an uncovered strut ratio .0.3 in ZES compared
with 140 (18.0%) cross sections in SES. Intracoronary thrombus
within stents was also not detected in ZES (10 (27.8%) in SES vs
0 (0.0%) in ZES, p = 0.001) (table 2). The uncovered (281/2524
(11.1%) vs 738/14 039 (5.3%), p = 0.010) and malapposed struts
(96/2524 (3.8%) vs 119/14 039 (0.8%), p,0.001) were fre-
quently found in the stents with intracoronary thrombus
NIH pattern and the mean neointima thickness were quite
different between the two stent groups (fig 3A). The thickness
of NIH at the thinnest part in ZES was similar to that at the
thickest part in SES. The proportion of NIH thickness beyond 1
SD was significantly lower in ZES (27.5% vs 58.3%) (fig 3B).
The heterogeneity score was also significantly lower in ZES
(table 2).
Predictors of uncovered and malapposed stent struts
Table 3 shows predictors of uncovered and malapposed struts.
The stent type, presence of a lesion typeB2 or C and diabetes
mellitus were independent predictors of uncovered struts, while
stent type and diabetes mellitus were independent predictors of
malapposed struts, respectively.
Clinical outcome
Follow-up angiography at 9 months was available in 120
patients (62 ZES and 58 SES). ISR occurred in eight and five
patients in the ZES and SES group, respectively. But, OCT
examination was possible in only four patients treated with SES
among 13 patients with ISR. In both groups there were no
deaths, non-fatal myocardial infarction and LST during the
9 months.
DISCUSSION
Our study showed that neointimal coverage of stent struts was
almost complete with a more homogeneous pattern in ZES at
9 months. Uncovered and malapposed struts were frequently
observed and the NIH pattern was more heterogeneous in SES.
Table 1 Baseline characteristics and quantitative coronary
angiography findings
Baseline characteristics ZES (n = 32) SES (n = 36) p Value
Age (years) 59.7 (8.4) 59.6 (8.4) 0.95
Male, n (%) 25 (78.1) 25 (69.4) 0.42
Acute coronary syndrome, n
(%)
17 (53.1) 21 (58.3) 0.67
Hypertension, n (%) 17 (53.1) 15 (41.7) 0.35
Diabetes mellitus, n (%) 12 (37.5) 13 (36.1) 0.91
Hyperlipidaemia, n (%) 18 (56.3) 17 (47.2) 0.46
Smoking, n (%) 8 (25.0) 10 (27.8) 0.50
Chronic total occlusion, n
(%)
0 (0.0) 1 (2.8) 1.00
Target vessel 0.33
LAD, n (%) 15 (46.9) 17 (47.2)
LCX, n (%) 4 (12.5) 8 (25.0)
RCA, n (%) 13 (40.6) 10 (27.8)
Lesion type B2 or C, n (%) 24 (75.0) 28 (77.8) 0.79
Stent diameter (mm) 3.1 (0.3) 2.9 (0.3) 0.004
Stent length (mm) 23.7 (5.9) 24.1 (6.4) 0.78
Maximal pressure (atm) 17.1 (2.4) 17.2 (2.0) 0.17
Postintervention QCA data
Mean RVD (mm) 2.9 (0.3) 2.8 (0.4) 0.32
MLD (mm) 2.8 (0.3) 2.7 (0.4) 0.04
DS (%) 2.0 (5.9) 5.9 (7.0) 0.02
Acute gain (mm) 2.1 (0.5) 2.0 (0.5) 0.33
9 Months’ follow-up QCA
data
Mean RVD (mm) 2.7 (0.3) 2.7 (0.4) 0.79
MLD (mm) 2.3 (0.4) 2.5 (0.4) 0.06
DS (%) 15.1 (8.2) 8.6 (13.4) 0.02
Late loss (mm) 0.5 (0.3) 0.2 (0.5) ,0.001
Values are presented as mean (SD) unless stated otherwise.
DS, diameter stenosis; LAD, left anterior descending artery; LCX, left circumflex artery;
MLD, minimal lesion diameter; QCA, quantitative coronary angiography; RCA, right
coronary artery; RVD, reference vessel diameter; SES, sirolimus-eluting stent; ZES,
zotarolimus-eluting stent.
Table 2 Optical coherence tomography (OCT) measurements at 9-
months’ follow-up
Tomography measurements
ZES
(n = 32)
SES
(n = 36) p Value
Cross sections (n) 696 777 –
Mean stent area (mm2) 7.8 (1.7) 6.6 (1.6) 0.006
Mean lumen area (mm2) 5.6 (1.5) 6.1 (1.7) 0.35
Mean NIH thickness (mm) 251.2 (110.0) 85.5 (53.4) ,0.001
Mean NIH area (mm2) 2.2 (0.8) 0.7 (0.4) ,0.001
Percentage of NIH 27.9 (9.1) 11.2 (7.1) ,0.001
Heterogeneity score 0.9 (0.8) 1.1 (0.7) ,0.001
Cross section with uncovered strut(s),
n (%)
18 (2.6) 308 (39.6) ,0.001
Cross section with uncovered strut ratio
.0.3, n (%)
0 (0.0) 140 (18.0) ,0.001
Presence of thrombi, n (%) 0 (0.0) 10 (27.8) 0.001
Values are presented as mean (SD), unless stated otherwise.
Heterogeneity score was defined as the difference between maximal and minimal
neointimal grade. (The status of NIH thickness at each cross section was divided into
four grades; grade 0, uncovered strut to total stent struts; grade 1, NIH thickness
,100 mm, which was not detected with intravascular ultrasound; grade 2, NIH
thickness between 100 and 200 mm, which was between minimal thickness
detectable using OCT and minimal mean thickness in bare metal stents; grade 3, NIH
thickness over 200 mm.11 The grade was determined as minimal grade including
>10% of stent struts at each cross section.)
NIH, neointima hyperplasia; SES, sirolimus-eluting stent; ZES, zotarolimus-eluting
stent.
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A previous pathological report demonstrated an association
between the lack of neointimal coverage in stent struts and
thrombus formation.12 Additionally, several angioscopy studies
demonstrated that thrombi were more prevalent in SES without
complete neointimal coverage than in BMS.13 14 Therefore,
detection of neointima of stents might have an important
clinical implication for predicting LST and deciding the optimal
duration of DAT.
Several imaging modalities can be used to study neointimal
coverage of stents. IVUS has been widely used to detect NIH
after stent implantation, but it has a critical limitation in
resolution that can only differentiate neointima thicker than
100 mm. Therefore, it is impossible to evaluate precisely
neointimal coverage in DES because previous studies, including
this study, have shown that a considerable portion (40%) of
neointima is ,100 mm in thickness.6 8 Angioscopy might be a
useful tool to evaluate neointima by providing direct visualisa-
tion, but it is limited by the unobtainability of quantitative
information.15
Recently, OCT has been introduced as a high-resolution
imaging modality with 10–20 mm of axial resolution.16 17 The
new intravascular imaging tool could clearly detect thin
neointima and provide quantitative information. Miyazawa et
al reported the rates of neointimal coverage were 50.2% in ZES
and 10.5% in SES at 8 months but other OCT data for SES
showed 85–91% of neointimal coverage between 3 and
6 months.6 8 15 Recently, Guagliumi, et al also demonstrated
that both ZES and SES had over 90% of neointimal coverage at
6 months.18 Our study produced a similar result showing that
88% of struts were covered by neointima. In addition, our study
showed that two-thirds of stent struts in SES and about 40% in
ZES were ,100 mm in neointimal thickness (fig 2A). These
findings imply that IVUS analysis for neointima might be
Figure 1 Representative optical coherence tomography images of zotarolimus-eluting stents (ZES) and sirolimus-eluting stents (SES). Completely
covered struts (A) and thick neointima (B) were seen in ZES but malapposed and uncovered struts (C) and thin neointima (D) were seen in SES.
Figure 2 Difference in the rate of uncovered stent strut, malapposition
and uncovered stent strut with malapposition on optical coherence
tomography between zotarolimus-eluting stents (ZES) and sirolimus-
eluting stents (SES).
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inaccurate owing to the relatively poor resolution. A large
portion of neointima thickness was ,100 mm on ZES as well as
SES. However, OCT can measure precisely the NIH thickness
compared with histology, which was demonstrated on a rabbit
carotid stent model (r = 0.85, p,0.001).19
This study showed that neointima covered almost all of the
stent struts and was evenly distributed in ZES compared with
that in SES (99.7% in ZES vs 87.7% in SES). This finding was
similar to previous angioscopy findings between SES and ZES
and compatible with those of BMS.5 8 15 20 The ODESSA study
showed that ZES had a significantly lower incidence of
uncovered stent struts than SES in both overlapping and non-
overlapping sites (0.02 vs 5.8% in an overlapping site and 0.01%
vs 6.0% in a non-overlapping site).18 Although these OCT and
angioscopy findings suggested that DAT for 9 months might be
acceptable in ZES, healthy neointima with intact functional
endothelium could be crucial to predict LST in the future and
the optimal duration of DAT. In addition, there were no data
suggesting that neointimal coverage detected by OCT is related
to clinical events or guidance for duration of DAT. Thus, more
data and longer-term follow-up are needed to investigate the
clinical implications.
A previous pathology study showed that non-uniform
neointimal coverage with DES, which was indicated by the
number of uncovered struts for each cross section, markedly
increased stent thrombosis risk, and lack of neointimal coverage
was associated with thrombus formation.3 Therefore, hetero-
geneous coverage of neointima over stent struts might also be
related to future thrombotic events. Our data demonstrated
that the absolute percentage of neointimal coverage was higher
in ZES than in SES, and ZES also has a homogeneous pattern of
neointimal coverage over stent struts. Analysable stent struts
were greater in ZES than SES, which might be related to fewer
artefacts around struts because of evenly covered neointima in
ZES. In addition, cross sections with uncovered struts were
significantly less frequently detected in ZES, and, significantly,
the ratio of cross sections with uncovered to total stent struts
.0.3 was not found in ZES, which was the morphometric
predictor of LST in the autopsy study.3
Malapposition is another possible predictor of stent throm-
bosis, though there has been some disagreement in the
literature.21 22 High-resolution OCT could be used to determine
the presence of malapposition. In this study, SES showed a
significantly higher rate of malapposition than ZES.
Malapposition in SES might be related to neointima growth
over stent struts by some magnitude but the clinical relevance
was not clear and more investigation is needed.
Study limitations
This study had several limitations. First, it was a non-
randomised study and the initial OCT images immediately
after implantation were not available. Second, this study had a
relatively small population who had a follow-up angiography
and OCT, which might have resulted in selection bias.
However, the number of stent struts (more than 15 000 struts)
was enough to evaluate neointima or malapposition. Third, the
quality as well as quantity of NIH might be important to
prevent thrombus formation. We could not evaluate the quality
of neointima in this study.
CONCLUSIONS
ZES, compared with SES, showed an almost complete homo-
geneous neointimal coverage of stent struts and low rate of
malapposition at 9 months after implantation.
Figure 3 Statistical distribution of neointimal hyperplasia (NIH)
thickness of zotarolimus-eluting stents (ZES) and sirolimus-eluting stents
(SES) (A). The proportions of NIH thickness beyond 1 SD between ZES
and SES. The percentage of NIH thickness outside 1 SD was significantly
lower in ZES than SES (B). The thickness of NIH at the thickest part or
thinnest part was the mean NIH thickness at three consecutive cross
sections at the corresponding part.
Table 3 Univariate and multivariate predictors of uncovered and
malapposed struts
Predictors Odds ratio (95% CI) p Value
Univariate predictors of uncovered struts
Stent type: ZES 0.89 (0.84 to 0.93) ,0.001
Lesion type B2 or C 1.07 (1.01 to 1.13) 0.03
Acute coronary syndrome 1.06 (1.01 to 0.13) 0.03
Diabetes mellitus 1.05 (0.99 to 0.12) 0.07
Multivariate predictors of uncovered struts
Stent type: ZES 0.87 (0.82 to 0.91) ,0.001
Lesion type B2 or C 1.10 (1.02 to 1.20) 0.02
Diabetes mellitus 1.06 (1.00 to 1.12) 0.04
Univariate predictors of malapposed struts
Stent type: ZES 0.98 (0.97 to 0.99) 0.01
Minimal luminal diameter before PCI 0.99 (0.96 to 1.00) 0.06
Acute coronary syndrome 1.02 (1.00 to 1.04) 0.09
Diabetes mellitus 1.03 (1.00 to 1.05) 0.09
Multivariate predictors of malapposed struts
Stent type: ZES 0.97 (0.95 to 0.99) 0.005
Diabetes mellitus 1.03 (1.01 to 1.05) 0.004
PCI, percutaneous coronary intervention; ZES, zotarolimus-eluting stent.
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